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By
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Associate Professor Audrey N. Player, Ph.D., Advisor
A previous study conducted in our laboratory demonstrated V-Myb Avian
Myeloblast Viral Oncogene Homolog Like 1 (MYBL1) gene over-expression in triple
negative breast cancer (TNBC) compared to normal, some luminal, and a subpopulation of
other TNBC. The MYBL1 gene belongs to the Avian myeloblastosis virus (MYB) family
and is classified as a proto-oncogene that functions as a strong transcription factor. The
MYBL1 gene is related to cancer progression which involves dysregulation of cell cycle
signaling, apoptosis and differentiation processes. A primary goal of our laboratory is to
further characterize MYBL1 gene expression in TNBC samples. To achieve this goal, we
performed a knockdown study to identify genes that co-operate with MYBL1 to affect the
phenotype of TNBC. The MDA MB231 TNBC cells were transduced with a short hairpin
ribonucleic acid (shRNA) lentiviral knockdown of the MYBL1 gene. When MYBL1 was
knocked down, MYBL2 and Adhesion Regulating Molecule 1 (ADRM1) genes were down
regulated and UBX Domain Protein 8 (UBXN8) gene was unregulated. Since MYBL2,
1
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UBXN8 and ADRM1 were affected by MYBL1 knockdown, for the current study, we
compared the gene expression patterns of MYBL2, UBXN8 and ADRM1 to that of
MYBL1 using different methods. Two approaches are utilized to achieve our goal. For
approach 1 we utilized polymerase chain reaction and immunohistochemistry to assess
RNA and protein expression levels, respectively. For the second approach, we analyzed
MYBL1, MYBL2, UBXN8 and ADRM1 transcript levels in TNBC patient samples
retrieved from Gene Expression Omnibus. Results from this project should assist in our
understanding of MYBL1 in TNBC.
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CHAPTER 1
INTRODUCTION

Background Information About Breast Cancer and Summary of
Breast Cancer Types
The development of adult-onset cancer is an extensive process that involves
amendments to the cell cycle, cell growth, cell death, and cellular differentiation that
specifically define the disease as cancer (26). The type of cancer is generally defined by
the tissue of origin and the progenitor cell type. For breast cancer, the cancers originate in
the breast and for some breast cancers the progenitor cells are luminal, myoepithelial, and
basal-like cells that line the lumen. The assumption is that different progenitor cells along
with the contribution of their microenvironments lead to breast cancer heterogeneity.
Breast cancers and all cancers are extremely heterogeneous. Breast cancer can be
defined based on their pathological diagnoses and based on molecular characteristics
(https://www.breastcancer.org/symptoms/types). A detailed list and short description of
breast cancers based on pathology and molecular signatures are listed below. To a large
degree, the different molecular diagnoses were defined by DNA microarray analyses.
DNA microarrays are a laboratory tool used to simultaneously identify gene expression
levels of thousands of genes. Many of the targeted therapies that are being used to treat
breast and other cancers are identified by microarray analyses.
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The different types of breast cancers are described below, but as a general
description, benign tissues are localized to their original site of origin (i.e., in-situ), they
are non-cancerous and non-life threatening. The invasive cancers spread (i.e., metastasize)
from their primary site to other organs, making them malignant and potentially life
threatening. Breast cancers often metastasize to bone, lung, liver, and brain. Recurring
cancers are cancers that return at the same or different locations in the body. Just like most
other cancers, breast cancers are identified and diagnosed based on their pathology and
molecular subtypes (50).
Pathologically Diagnosed Types of Breast Cancers
Even though there are many types of breast cancer in this category, most of them are
rare. A detailed list of some o the pathologically diagnosed types of breast cancers include:
•

Cribriform Carcinoma of the Breast - Cribriform cancers are rare invasive
cancers. The cancers are low grade (i.e., look normal), but appear to have ‘holes
or display cribriform-like configurations.

•

Ductal Carcinoma in Situ (DCIS) - DCIS is a non-invasive carcinoma which
originates in the milk ducts of the breast. DCIS does not metastasize; however,
DCIS patients have a significant risk of developing invasive cancers later. It
occurs at ~15%.

•

Inflammatory Breast Cancer (IBC) - IBC is difficult to detect because of it
appears as “sheets” rather than “lumps”. IBC is an invasive cancer that is very
aggressive as well as rare.
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•

Invasive Ductal Carcinoma (IDC) - IDC is the most common kind of breast
cancer. It is detected in around 60-70% of breast cancers. IDC is an invasive
cancer that occurs in the milk ducts.

•

Invasive Lobular Carcinoma (ILC) - ILC cancers are invasive cancers that
originate in the lobules of the breast. ILC cancers occur in approximately 15%
of patients, making it the second most common type of cancer.

•

Lobular Carcinoma in Situ (LCIS) - LCIS is an abnormal cell growth in the
milk glands (lobules) that can signal a higher risk of future invasive cancer.
LCIS is also known as a lobular neoplasia (i.e., benign).

•

Male Breast Cancer - Breast cancer in men is very rare, occurring in less than
1% of men. Although they are rare, they are invasive.

•

Medullary Carcinoma of the Breast - Medullary carcinomas occur in around
3% of patients. Medullary carcinomas appear as soft, flesh-like masses. The
flesh like masses resemble the brain’s medulla. Medullary

•

carcinomas are rare and invasive ductal carcinomas. These cancers are often
‘cluster near TNBC’ indicating genetic similarity.

•

Mucinous Carcinoma of the Breast - Mucinous Cancer is a rare cancer that
originates in the milk ducts. It has abnormal cells “floating in a pool of mucin”.
The mucin then becomes a part of the tumor.

•

Paget’s Disease of the Nipple - Paget’s disease is a breast cancer involving
cancer cells around the nipple and breast ducts. Paget’s disease can be mistaken
for dermatitis because skin around the nipple is flaky, and the nipples are
inverted and hardened with an appearance resembling eczema.
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•

Papillary Carcinoma of the Breast - Papillary cancers have small finger-like
projections or papules and well-defined borders. They are also a rare invasive
ductal breast cancer.

•

Phyllodes Tumors of the Breast - Phyllodes cancers start in the stromal tissue
in the breast. The tumor cells grow in a leaf-like arrangement. The cancer
happens in less than 1% of breast cancer patients.

•

Tubular Carcinoma of the Breast - Tubular breast cancer is a subtype of
invasive ductal breast cancer. It accounts for less than 2% of all breast cancers.
Like other types of invasive ductal cancer, tubular breast cancer originates in
the milk ducts of the breast. It then spreads to the tissues around the duct
becoming cancerous. Underneath a microscope, tubular carcinomas look like
tubes.

Molecular Breast Cancer Types
The prevalence and definitions of molecular breast cancers are presented in Figure 1.
A more elaborate description is given below (31).
(https://www.breastcancer.org/symptoms/types). Some breast cancers are referred to as
luminal or triple negative / basal-like subtypes. These designations are based on the
location of the progenitor cells for luminal and triple negative / basal-like cancers Figure 2
(64).

Molecular Subtypes of Breast Cancer are Luminal A/B, Triple Negative/Basal-like,
HER2-enriched, and Normal-like
Yersal et al. (71) conducted a study to characterize biological subtypes of breast
cancers. Yersal et al (71) classified luminal A cancers as estrogen receptor positive,
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progesterone receptor positive, and HER2 negative. Luminal B are classified as estrogen
receptor positive, progesterone receptor positive, and HER2 positive/negative (71). The
prognoses of Luminal B cancers versus Luminal A cancers are marginally adverse (71).
Triple negative/basal-like cancers are estrogen receptor, progesterone receptor, and
HER2 negative (71). While TNBC and basal-like are similar due to gene expression levels,
data indicate there is ~25% difference between them (71). A more thorough description of
TNBC is explained below. HER2neu-enriched breast cancers are estrogen receptor
negative, progesterone receptor negative, and HER2 positive. Normal-like cancers are like
Luminal A cancers because they are estrogen receptor positive, progesterone receptor
positive, and HER2 negative. Although they appear low grade with low nuclear protein
Ki67 (Ki67) levels (71).

Triple Negative Breast Cancer
Transcriptome data analyses suggest the progenitor cells for TNBC are localized to
the basement region of the milk ducts in breast, while luminal progenitor cells or localized
nearest to the lumen regions (Figure 2). TNBC are defined as a single subtype. However,
using DNA microarray and clustering analyses, Lehmann et al. (38) showed that TNBC
are a complex, heterogenous subtype that can be further divided into 6 sub-categories. The
6 sub-categories were defined by specific gene expression profiles, and later, mutational
studies. Lehmann et al. (38) defined the subtypes as (a) Luminal androgen receptor (LAR)
also known as molecular apocrine cancers, (b) basal-like 1 (BL1), (c) basal-like 2(BL2),
(d) an immunomodulatory group (IM), (e) a mesenchymal group (M), and (f) a
mesenchymal stem-like sub-group (MSL). The LAR subcategory includes estrogen
receptor samples that overexpress androgen receptors and hormonal regulatory genes. The
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basal-like 1 (BL1) group is enriched in genes associated with the ribonucleic acid (RNA)
polymerase pathway, cell cycle and cell division signaling pathways. TNBCs that are
basal-like 2 (BL2) originate in the myoepithelium and include genes involved with growth
factor signaling processes, gluconeogenesis, and glycolysis. Immunomodulatory (IM)
cancers are like medullary breast cancers. They are enriched with genes that include
immune signaling pathways, natural killer cell pathways, cytokine signaling pathways, and
antigen identification and processing pathways. The M and MSL sub-category include
genes aligned with cell motility, proliferation, mesenchymal-like differentiation, and
extracellular matrix proteins. Lehmann et al (38) studies were instrumental in defining
TNBC. Results from their data led to identification of potential TNBC biomarkers and
improvements in predicting patients’ response to therapies.

Figure 1:

Molecular Signatures and Prevalence of Breast Cancer Types (31)
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Figure 2:

Anatomical Position of Luminal Breast Cancer vs TNBC Progenitor
Cells Near Breast Lumen

Breast Cancer Statistics and Other Information Related to TNBC
According to the American Cancer Society, about 1.9 million new cancer cases were
diagnosed in 2021 with more than 600,000 estimated deaths (1). In 2021, approximately
281,550 newly diagnosed cases of invasive breast cancer will emerge in women, and about
43,600 women will die from breast cancer in 2021 as reported by the American Cancer
Society (3). The American Cancer Society states that 1 in 8 women (13%) will be
diagnosed with invasive breast cancer in their lifetime, as well as 1 in 39 women (3%) will
die from breast cancer (27). Patients that die are either diagnosed with later stage cancer,
or they die due to a lack of therapeutic options (13,51,53). TNBC are basal-like cancers
that account for 10-20% of all breast tumor heterogeneities (28).
Approximately 75% of TNBC are basal-like subtypes, which are defined by gene
expression profiling (55). Compared to other cancers, the time from initial diagnosis to
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death and the time-to metastasis is shorter in patients with TNBC (6,51). In comparison to
an 80% survival rate in other subtypes, 20% of the TNBC patient population survive after
a 5-year period (54). Because TNBC being negative for all three common receptors,
conventional hormone therapies like tamoxifen and anti-HER2 antibody therapies like
trastuzumab cannot be used to treat TNBC patients (16). Tamoxifen and trastuzumab are
used for patients with positive receptor status, making it ineffective for nearly all TNBC
patients (16). There are few therapeutic options for treatment of TNBC patients. Several
targeted gene therapies are currently being consider; however, standard care includes
chemotherapy and radiation therapy (8). For this reason, it is vital to further characterize
TNBC and identify genes that are associated with the tumorigenic process. Once these
novel genes have been identified, they can be studied for their possible clinical utility and
ultimately used as targeted therapies to affect patient survival.

CHAPTER 2
LITERARY REVIEW

BACKGROUND
Discovery of the MYB Family Genes
The focus of this study is to further characterize MYBL1 in TNBC. MYBL1 is a
member of the MYB family of human genes, which also consists of c-MYB and MYBL2.
c MYB was the first member of the family to be identified and characterized. The c-MYB
gene was identified based on its similarity to the Avian Myeloblastosis Virus (AMV) vMYB gene sequence (21). AMV is a highly oncogenic chicken leukemia virus which
transforms immature hematopoietic cells. Compared to c-MYB, AMV’s N-terminal and
C-terminal regions are truncated, and the gene contains 16 intragenic point mutations.
Using c-Myb as a probe, MYBL1 and MYBL2 were discovered in a complimentary DNA
(cDNA) library. All the genes are strong transcription factors that regulate transcript and
small RNA expression (39). Sequence analyses reveal both similar and divergent regions
in all three MYB family genes. Similarly, the MYB family genes can transcriptionally
regulate some of the same and different genes. Each of the MYB family genes is unique in
some aspect. Unique to MYBL1, the gene regulates the meiotic process in testis (59) and
is over expressed in normal testes during spermatogenesis.
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MYB Family Sequences Comparison to Highlight Shared Gene and Unique
Gene Expressions
Protein sequences of the MYB family genes share both similar and different regions
within their sequence. The genes are similar at the N-terminal DNA binding domain
(DBD), their internal transactivation domain and the C-terminal regulatory domain (9). The
DBD demonstrates the highest degree of homology, while the transactivation and Cterminal regulatory domain share less homology between the MYB family genes. The
NCBI Web CD Search Tool can be used to locate the positions of these regions (44).
Collectively the domains are responsible for defining their recognition sites, protein:
protein interactions with other transcription factors, coactivators, and sites susceptible to
epigenetic modifications. The DBD are an estimated 90% similar between the MYB family
genes suggesting that MYB family genes can recognize some of the same genes. Using a
reported gene strategy, Rushton et al demonstrated the extent to which MYB family can
regulate transcriptional expression of some of the same genes and uniquely different genes.
The DBD region is a part of the activation and transcriptional repressor complexes (9).
Because the DBD is so homologous between the MYB family genes, investigators suggest
that differences in the C-terminal lead to differential regulation of the genes and ultimately
their functions. Studies of c-MYB show the N-termini is associated with intra and inter
negative regulator functions and truncation of the C-terminal region result in tumors (21).
In addition to the domains noted above, MYB family proteins contain a SANT
domain defined by binding to Swi3, Ada2, N-Cor, and TFIIIB genes. SANT domain allows
for chromatin remodeling as well as transcriptional regulation. Presence of the SANT
regions suggest epigenetic regulation of the MYB family genes.
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MYBL1 Expression in Copious Tissues and its Relationship with the
Cell Cycle Signaling and Tumorigenesis
Analyses of the MYB family of genes and the genes that they regulate are good
resources to examine in search of biomarkers. The genes are good candidates because they
are putative oncogenes (73) and are related to processes directly tied to tumor pathogenesis.
Several years ago, c-MYB gene was considered a possible therapeutic target for luminal
breast because the gene was (a) overexpressed in these tissues (b) vital to growth and cell
cycle signaling, and (c) the gene gave rise to tumors in mice (41). Liu et al designed small
molecules and applied c-MYB RNA interference (RNAi) strategies to study the use of cMYB as a target for therapy (42). Liu’s experiments were performed several years ago, but
today fewer studies are being published touting c-MYB as a target (41). c MYB does not
appear to be pursued with the same vigor as earlier.
Our laboratory and others are considering MYBL1 and MYBL2 for their potential
clinical utility. Compared to c-MYB, less is known about MYBL2 and even less about
MYBL1 associated processes.
The first experiments characterizing the MYBL1 gene showed the genes’
involvement in cell cycle signaling. Ziebold et al. (75) conducted one of the first
experiments that demonstrated a connection between MYBL1 and cell cycle signaling.
Their experiments revealed MYBL1s’ involvement in GAP 1 phase (G1) to Synthesis (S)
phase progression. Data show that MYBL1 is indirectly affiliated with phosphorylation of
cyclin dependent kinases. Marharmati et al. (45) show that MYBL1 works with c-MYB to
mediate progression to S phase in smooth muscle cells.
The DREAM or LINC complex is a large assortment of genes that interact in
various combinations to regulate cell cycle signaling processes (19,20,56). MYBL1 and
MYBL2 are a key part of this complex and subsequent signaling processes. According to
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genecards.org, the DREAM complex includes the “elongation factor 4 (E2F4), elongation
factor 5 (E2F5), LIN9 complex DREAM MuvB core complex component (LIN9), Lin-37
DREAM MuvB Core

Complex Component (LIN37), Lin-52 DREAM MuvB Core

Complex Component( LIN52),

Lin-54 DREAM MuvB Core Complex Component

(LIN54), MYBL1, MYBL2, Retinoblastoma Like 1 Protein (RBL1), Retinoblastoma-Like
2 Protein (RBL2), Retinoblastoma Binding Protein 4 (RBBP4), Transcription Factor Dp1
(TFDP1) and Transcription Factor Dp2 (TFDP2) proteins (19,20,56)”. E2F4, LIN37,
TFDP2, MY2L1 and MYBL1 genes (of course) were downregulated in our MYBL1
knockdown study (June 2021).
Relationship of MYBL1 to Tumorigenesis
MYBL1 is a putative oncogene which is associated with regulation of cell
proliferation, differentiation, and apoptosis, events all of which are hallmarks of cancer.
Based on these observations, more and more investigators are beginning to consider
MYBL1 as a potential gene to study for its role in cancer. In most of the MYBL1 cancer
studies, the gene is over-expressed and the mechanisms leading to dysregulation in many
of the cancers is not known. In a few cases the type of mutations has been identified.
Several studies in leukemia reveal that changes in expression of MYBL1 gene is triggered
by amplifications, rearrangements, and translocation events in tumors (33, 63). The
translocations often involve fusions with the Nuclear Factor I B (NFIB) gene (33).
MYBL1 gene is overexpressed in Burkitt’s lymphoma (5,23), Triple Negative
Breast Adenoid Cystic Carcinoma (63), Cutaneous Adenoid Cystic Carcinoma (37), and
TNBC (63). Arsura et al. (5) show survival of lymphomas is maintained by MYBL1 and
c-MYB dysregulation at the GI phase of the cell cycle. Their data show the correlation
between MYBL1, cell signaling, apoptosis and cancer. Liu et al. (41) examined 181 breast
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cancer patient samples using the microarray platform followed by multivariant analyses.
The authors identified MYBL1 and 9 additional genes that correlated with poor prognosis
in receptor positive patient samples.
Of the 9 genes identified by Liu et al., 3 of the genes were differentially expressed
in our current receptor negative MYBL1 knockdown (41,52). The genes include MAF1,
Dual Specificity Phosphatase (DUSP7), and Solute Carrier Family 25 Member
1(SLC25A1).
Gorbatenko et al. (25) examined MYBL1 expression levels in basal-like breast
samples, normal-like breast samples, and luminal breast samples. Gorbatenko et al. (25)
observed high levels of MYBL1 in basal tumors (Figure 4) (arrow). Note that MYBL1 and
MYBL2 expression levels in basal-like cancers are similar. Based on gene expression
profiles, basal-like cancers and TNBCs are ~75% similar, so we can infer a similar pattern
of expression in TNBC. Player et al. observed a similar pattern of overexpression in TNBC
patients (53) (Figure 5). For all known genes, Protein Atlas.org gathers RNA, protein
staining patterns, pathology and other data related to the gene. More recently the site has
included RNA seq profiles generated from cancers. The RNA seq profile for MYBL1
expression in a range of cancer are given in Figure 6. Note MYBL1 levels are highest in
breast cancer validating (at least) high levels of the gene in breast cancer. The cancers were
not examined based on subtype.
MYBL1, MYBL2, UBXN8 and ADRM1 Genes Screened as Part of This Study
It is well established that MYB family genes are co-expressed in a lot of tissues
and cancers (24). Studies show that c-MYB can regulate MYBL1 and MYBL2, and
MYBL1, c-MYB and MYBL1 are often co-expressed in the same cell lines and cancer
patient samples (12, 24, 60).

14
We examined several GEO microarray datasets where c-MYB was targeted for
knockdown or indirectly knocked down in breast cancer cell lines. These data showed that
when c-MYB is down-regulated, MYBL1 and MYBL2 are also down-regulated. These
data validate the ability of the genes to co-regulate each other. GEO did not contain
MYBL1 knockdown datasets. The goal of our laboratory is to further characterize MYBL1
in TNBC with the first approach directed at identifying genes that might co-operate with
MYBL1 in affecting the cancer genotype in these cells. Towards this goal, the knockdown
of MYBL1 is expected to reveal genes that are either directly or indirectly affected by
MYBL1 knockdown. This would be consistent with previous data that reveal c-MYB,
MYBL1 and MYBL2 can regulate each other. For our knockdown study, we found that
when MYBL1 was knocked down, MYBL2 and Adhesion regulating molecule 1
(ADRM1) were downregulated, and UBX Domain Protein 8 (UBXN8) was upregulated.
Although the MYB family genes have been shown to be co-expressed, this is the first
experiment that showed targeted knockdown of MYBL1 led to down-regulation of
MYBL2. c-MYB is not expressed in MDA MB231 cell line, so c-MYB served as a negative
control for assessment of our procedure. The MYBL1, MYBL2, UBXN8 and ADRM1
expression levels will be assessed as part of this current study.

UBXN8 Gene
In addition to MYBL1 and MYBL2 the UBXN8 gene is being examined to assess
its gene expression profile. The UBXN8 gene appeared to be downregulated when MYBL1
was knocked down by shRNA MYBL1 lentiviral transduction, as a result the gene was
screened for its pattern of expression as part of the current study. UBXN8 gene is associated
with endoplasmic reticulum directed degradation of misfolded proteins. The gene is
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localized to both the endoplasmic reticulum and nucleus compartments of the cell. Not
much is known about UBXN8, but in certain cancers it functions as a tumor suppressor
gene. Over-expression promotes cell cycle arrest and inhibits proliferation and colony
forming ability in acute myelogenous leukemia (69). The gene is downregulated by
hypermethylation of its promoter region, which in turn leads to leukemogenesis (69). In a
separate study, Liu et al. showed that hypermethylation of UBXN8 could be used for
diagnosis and prognosis of gastric cancer. One could speculate that UBXN8 functions as a
tumor suppressor gene in TNBC because the gene is downregulated while MYBL1 is
upregulated. Then when MYBL1 is knocked down, the gene is upregulated activating its
suppressor function. We will address this speculation later.
ADRM1 Gene
Adhesion Regulating Molecule 1 (ADRM1) gene is downregulated when MYBL1
was knocked down by shRNA MYBL1 lentiviral transduction, as a result the gene was
screened for its pattern of expression as part of the current study. ADRM1 is involved in
ATP dependent
degradationofofubiquitinated
ubiquitinatedproteins.
proteins.Like
LikeUBXN8,
UBXN8,ADRM1
ADRM1 plays
playsaarole
role
dependent degradation
in removing
proteins. ADRM1
ADRM1 however
removing misfolded,
misfolded, damaged
damaged proteins.
however functions
functions as
as aa proteasomal
proteasomal
ubiquitin
The breast
gene is
ubiquitin receptor
receptor.(http://www.proteinatlas.org/ENSG00000130706-ADRM1).
The gene is up regulated in gastric, colon, prostate, ovarian and
up
regulated
colon,
prostate,
ovarian and
cancer.
Wu etwith
al (67)
found
that
cancer.
Wu etinalgastric,
(67) found
that
over expression
of breast
ADRM1
correlates
poor
prognoses
over
expression
of ADRM1
poor
prognoses
in receptor
breast
cancers.
in receptor
positive
breastcorrelates
cancers. with
Their
data
show that
ADRM1positive
is a more
reliable

Their
data marker
show that
ADRM1receptor
is a more
reliable
prognostic
marker
in estrogen
receptor
prognostic
in estrogen
positive
cancers
compared
to receptor
negative

cancers.
ADRM1
will be screened
its possible relationship with MYBL1
positive Nonetheless,
cancers compared
to receptor
negativefor
cancers.
Nonetheless,
be screened for its possible relationship with MYBL1 in TNBC in the
in TNBC in theADRM1
currentwill
study.
current study.

16

Figure 3:

HER2, c-MYB, MYBL1, MYBL2 in Normal, Basal (TNBC)
LumA, LumB, HER2 Patient Samples
Arrow points to MYBL1levels in basal (TNBC).
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Figure 4:

Analyses of MAIRE Patient Samples for Differential Gene Expression of
MYBL1 and Other Candidate Genes
TNBC (red bars across the top) are compared to all other sample types
(including normal, luminal A/B, HER2neu; yellow). Data shows most (not all
TNBC cluster together based on analyses of our 6 gene list. These data led to
identification of MYBL1. A and B are the same except the TNBC that cluster
with ‘all other samples’ were removed. TNBC clustering with all others are
identified by the individual ‘red patient samples that appear mixed with the
yellow’. 168 patients are across the top, genes on the slide. Red bars over the
red regions designate samples over-expressed for a particular gene. Gene
indicates under-expression for a particular gene. Results generated using
microarray.
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Figure 5:

MYBL1 Transcript Levels Determined in Various Types of Cancer
RNA seq data retrieved from ProteinAtlas.org. The cancers were not
processed by molecular subtype.

CHAPTER 3
DESIGN OF THE STUDY

MATERIALS AND METHODS
Cell Lines
The cell lines used in this study are MCF7 (luminal receptor positive cells), MDA
MB231 (TNBC receptor negative cells), and MCF10A (non-tumor receptor negative
cells).

The cell lines were purchased from the American Type Culture Collection

(ATCC®) atcc.org (Manassas Virginia) and used within 1 year of purchase. The cells were
fed twice a week using Dulbecco’s Modified Eagle Minimum essential media (DMEM)
with 1% penicillin and 10% serum and maintained in a 37OC incubator with an additional
5% CO2. The cells were harvested when they reached 80-90% confluency with a 0.25%
trypsin solution (Millipore, Sigma, St. Louis Missouri) and either used for experiments or
sub-cultured at a lower density.
The patient datasets were obtained from Gene Expression Omnibus (GEO) and
included Maire et al (43) (GSE65216), Thorner et al (61) (GSE21371), Muthukaruppan
et al. (48) (GSE37820), Richardson et al. (58) (GDS2250), and Farmer et al (18)
(GDS1329). The datasets were generated using microarray, so the data contain transcript
level analyses.
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Ribonucleic Acid (RNA) Isolation
The cell lines in this study were grown in T75 dishes to roughly 90% confluency
and harvested by adding 1mlliliter (ml) Trizol (Thermo Fisher Scientific (Waltham
Massachusetts) to the culture dish. The sample was collected, and 200 microliters (ul)
chloroform was added. The solutions were mixed and centrifuged at 12,000 revolutions
per minute (RPM) to separate the aqueous RNA top layer. The aqueous layer was placed
in a clean tube with 500ul of 95% ethanol and places at -20ºC for 30minutes. RNA was
collected by centrifuging the samples for 30 minutes at 10,000 RPM. The RNA pellet was
dried, resuspended in 20ul of clean water and heated at approximately 60ºC for 1 minute.
The purity of the RNA was determined by spectrophotometric analysis. One ul of the RNA
solution was added to 9ul of water and the 260/280 absorbance ratio was determined. An
A260/280 ratio of 1.8-2.0 represents purified RNA. An aliquot of the RNA mixture was
also retrieved for gel electrophoresis. One ul of RNA was added to the RNA sample buffer
and heated at roughly 60ºC for 1 minute. The 10ul sample was added to a 1% agarose gel.
The agarose gel was prepared using of 1 gram of agarose, a 1x solution of 3-(Nmorpholino) propane sulfonic acid (MOPs) buffer, 2µl ethidium bromide and 7%
formaldehyde. The RNA sample was considered suitable for downstream use if prominent
28S/18S ribosomal RNA bands were observed at equal density.
Generating Complementary DNA (cDNA)
The cDNA was produced using an iScript cDNA kit (Bio-Rad, Hercules CA,
USA). A 20 ul mixture containing approximately 1 ug of total RNA, 5x iScript buffer,
reverse transcriptase, random hexamers, the Oligo dT mixture, deoxyribonucleic
triphosphate acids (dNTPs), and water was combined. The 20 ul mixture was placed at
45ºC for an hour. The mixture was then placed at 85ºC for ~3 minutes to inactivate the
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reverse transcriptase. The mixture was cooled and 80 ul of water was added. The cDNA
was placed at –20ºC until it was used for polymerase chain reactions (PCR) or -80degrees
for long term storage.
Process for Generating Primers
To generate primers for each of the target genes in this study, the primer3 (35)
program (http://bioinfo.ut.ee/primer3-0.4.0/) was utilized. The nucleotide sequences for
our target genes were retrieved from Affymetrix NetAffx (15)
(http://www.affymetrix.com/estore/analysis/index.affx). So that all our genes could be
examined via polymerase chain reaction (PCR) using the same PCR cycle conditions,
the default Primer3 conditions were applied. The only parameter that was changed in
the program was the amplicon size which ranged from 200-300 nucleotides for each
gene. To determine the specificity of the primer-sets designed by Primer3, the primersets were examined using The University of California Santa Cruz Genome database
(64) (https://genome.ucsc.edu/) in silico PCR analyses program.
Primer-sets were submitted online to IDTDNA.com (Coralville, Iowa),
synthesized, quality controlled at the IDTDNA facility, then shipped to Texas Southern
University within 48hours of purchase. Table 3 lists the primer sequences for the genes
used in this study.
Polymerase Chain Reaction (PCR)
The PCR procedure was used to process samples for assessment of their
differential gene expression levels. PCR was also used to validate the microarray results.
Even though the microarray is an invaluable tool, the results must be experimentally
validated. PCR was performed using cDNA. The PCR reactions each contained 2ul
(~0.5uM) of forward and reverse primers, 2ul of cDNA (which was generated above),
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10ul of 2x thermostable DNA polymerase I TAQ polymerase master mix (optimized for
TAQ enzyme, dNTPs and TAQ buffer; Life Technologies, Carlsbad California), and water
up to 20ul. The primers generated for each gene were specific for that gene. The samples
were placed in PCR quality tubes and positioned in the Bio-Rad Thermal Cycler (Hercules
California). The cycler conditions were (a) 5 minutes at 95ºC degrees (b) 30-32 cycles for
30 seconds at 95ºC, followed by 30 seconds at 58ºC degrees, then 30 seconds at 78ºC.
Gel Electrophoresis
The gel electrophoresis was performed to analyze the PCR products using a 2%
agarose gel. The agarose gel contained 2 grams of agarose added to 100 ml of 1X
Tris/Borate/EDTA (TBE) buffer. The mixture was heated, cooled, and an additional 1ul
of Ethidium Bromide (EtBr) was added prior to pouring the gel mixture in the chamber.
So that direct comparisons between transcript levels could be determined, precisely 10 ul
of the PCR product and 2ul of sample buffer were loaded onto the gel for electrophoresis.
Densitometer
LI-COR Imaging System (Lincoln Nebraska) it was used to visualize the PCR
products on the gel. The densities of the amplicons were assessed using the LI-COR
software. All the values were normalized in comparison to the control gene.
Protein Interaction Analyses
The Search Tool for the Retrieval of Interacting Genes/Proteins (STRINGTM)
program (60) was utilized to examine and demonstrate the protein interactions between the
candidate genes. STRINGTM analysis relies on the interrogation of millions of data points
that was produced using experiments, theory, and published studies. STRINGTM analyses
were also utilized to determine protein interactions between MYLB1, MYBL2, UBXN8,
and ADRM1.
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Immunohistochemistry Staining
A low-density paraffin embedded breast cancer TNBC microarray was purchased
from BioMax.US (BR498) for this study. The tissue array was deparaffinized by placing
the slide in xylene for 15 minutes, followed by rehydration in 100% alcohol for 15
minutes, 95% alcohol for 15 minutes, 70% alcohol for 15 minutes, and clean water for 15
minutes. The slides were rinsed in PBS for 5 minutes. Antigen retrieval was performed
by adding the tissue slide to a boiling hot 1x citrate solution (H-3300-250, Vector
Laboratory, Burlingame CA) for 20 minutes. The slide was rinsed in PBS for 5 minutes,
a PAP blocking pen was applied, then the antibody blocking serum (normal goat or horse
serum; supplied with PK-6000; ABC HRP peroxidase staining kit, Vector Laboratory)
was added and the slides incubated at room temperature for 30 minutes. Excess serum was
removed, and the tissues were incubated overnight at 4oC with their corresponding
antibody. ADRM1 human anti-mouse was purchased from Santa Cruz Biotechnology
(Santa Cruz CA; sc-166754) and used at a 1:1000 dilution. CD31 blood vessel anti human
mouse antibody control was purchased from Santa Cruz Biotechnology (sc-43411) was
used at a 1:1000 dilution. Four micrograms per sample of MYBL1 antibody (anti human,
mouse antibody; Millipore Sigma, HAP008791) was added to the tissue. Antibodies were
diluted in normal horse serum.
The next day, slides were rinsed twice, 5minutes each in PBS/Tween, then
incubated with the biotin-conjugated universal secondary antibody at room temperature
(RT) for 30 minutes. The slides were rinsed as before and incubated with the SABC
reagent at RT for 30 minutes. The tissue was washed and ‘developed’ by adding the DAB
peroxidase substrate solution (Vector Laboratories: SK-4600). The samples were allowed
to develop and stopped once a desired color was obtained. The reaction was stopped by
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placing the slide in distilled water. The slides were briefly counterstained using
hematoxylin. The slides were dehydrated by incubation in clean water, 70% alcohol, 95%
alcohol, 100% alcohol (each for ~3minutes) followed by xylene for 15 minutes. The slides
were dried and permanent mounted.

CHAPTER 4
RESULTS AND DISCUSSION
This chapter discusses the materials and procedures performed prior to this study
but critical to interpretation of the results. The data generated as part of an earlier study:
shRNA knockdown of MYBL1 in MDA MB231 cells.
The knockdown was performed prior to this proposal, however because it was a
critical part towards generating the candidate genes studied here, the procedure for
achieving the knockdown were described here in Figure 6. The aim of the knockdown
study was twofold. The first aim was to further characterize TNBC. Being that MYBL1
was a gene of interest, the second aim of the knockdown study was to determine genes
that were directly/indirectly associated with MYBL1 in TNBC. As summary of the
procedure, the MYBL1 shRNA lentiviral particles and the scramble control particles were
purchased from Origene (Cat # TL303089V; Rockville Maryland). We purchased four
MYBL1 target specific particles (packaged from the pGFP-C-shLenti vector; labeled
LVA, LVB, LVC, LVD) along with the control from Origene. We transduced each of the
lentiviral preparations into MDA MB231 (at a MOI of 10:1) and screened for their ability
to decrease MYBL1 levels in the TNBC cell line. MDA MB231 cells were incubated with
the targeted or scrambled viral particles for approximately 72 hours with polybrene (sc134220; Santa Cruz Biotechnology, Dallas Texas) in complete cell culture media.
.
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Following removal of the lentiviral particles, fresh media was added to the cells
along with 1ug/ml puromycin (CAS 53792; Santa Cruz Biotechnology, Dallas Texas).
The LVA lentiviral corresponding to the CTGATCCTGTAGCATGGAGTGACGTTAC
sequence, demonstrated the highest downregulation of the MYBL1 mRNA. As a result,
the LVA particles were used for future experiments.

Figure 6:

Synopsis of the shRNA Procedure
Transgene of interest and the necessary cis elements for RNA production
and packaging are transfected into HEK cells. Before being sent to
customers for transduction, the packaged particles are generated and
harvested (10). In this figure, HEK293T cells are used to generate viral
particles that are transduced into cardiomyocyte cells.

RNA and protein analyses of the LVA shRNA MYBL1 particles demonstrating
knockdown of MYBL1 RNA (a) and protein in cell line preparations are shown in Figure
8. RNA was processed as described in the Methods section above. Protein expression
levels were determined using Western Blot analyses.
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Western Blotting
The western blot procedure was performed as referenced in our publication (June
2021). As documented, the antibodies used for the assay are described below: Antibodies:
Both antibodies described below were generated as mouse monoclonals. Actin was used
at a 1:104 dilution (NB600-501SS; Novus Biologicals LLC, Littleton CO), and MYBL1
was used at a 1:500 dilution (sc-514682; Santa Cruz Biotechnology, Santa Cruz CA).
Secondary HRP conjugated Anti mouse antibody (HAF007; R and D Systems,
Minneapolis, MN) was used at a dilution of 1:4000. Western blotting results were
visualized with the Clarity Western ECL substrate (Bio-Rad, Hercules, CA, USA) on a
LICOR digital imaging system (LI-COR Biotechnology, Lincoln, NE).
Microarray and Data Analyses
RNA was purified from a scrambled and MYBL1 knockdown preparations of
MDA MB231. The RNA was shipped overnight to the University of Texas Southwest
Core Facility (UTSW; Dallas Texas, USA). The UTSW core facility prepared the RNA
and hybridized it to the Affymetrix Clarion microarray gene-chip which includes
approximately 186,000 probe sets (i.e., transcripts, splice variants, siRNA and snoRNA)
(see figure 7). The facility provided our laboratory with the hybridization results. The data
analyses were conducted (at TSU) by Dr Player utilizing the Affymetrix TAC 4.0 software
(Thermo Fisher Scientific, Waltham Massachusetts). The data were normalized utilizing
the Robust Multi Array (RMA) program. Utilizing the Limma Bioconductor analysis, the
differentially expressed gene levels were produced. If the probe-sets displayed at
minimum a 4-fold difference in gene expression between a gene in the MYBL1 LVA
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microarray dataset compared to a gene in the scramble microarray dataset, the gene was
chosen for further analysis. A 2-fold difference is the industry standard, but the higher the
cut-off, the more reliable the resulting data. Gene Ontology analysis (46) was utilized to
interrogate the differentially expressed candidate genes. Microsoft Excel was used to
create transcript plots and analysis. Molbio-tools
(http://www.molbiotools.com/listcompare.html)

was

used

to

compare

several

differentially expressed gene-lists.

Figure 7:

The Affymetrix Microarray Genechip
Immobilized sense strands complementary to the target sequence are on the
genechip. Gene-chips containing either 56,000 transcripts or 186,000
transcripts, splice variants and small RNAs displayed as blue dots in the
middle figure. Total RNA is labeled and hybridized to the genechip. High
copy number corresponds to intense probe-set signals; displayed as lighter
spots in the far-right magnified pane. Control sequences at known
concentrations are also supplied on the gene chip and used to determine copy
number (15).
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Based on differential gene expression in microarray and comparison to existing cell
line and patient sample datasets, 19 genes were selected for our final list of candidate
genes. MYBL1 (which was knocked down) is a strong transcription. As a result, we asked
‘of the genes on our list, which ones are direct transcriptional targets of MYBL1’? Online
analyses using the ChipX (15) high density transcription factor binding libraries can
address this question. ChipX interrogates a larger number of transcription factor (TF)
library databases each containing information from thousands of TF experimental assays.
Each TF experimental assay assesses the binding of > 1600 well defined transcription
factors and accessory proteins. The data presented in Table 2 – was not experimentally
validated (by binding assays) but the suggestion was ‘our 19 candidate genes show
concordant enrichment of MYBL1 binding’. MYBL1 ranked 11th out of 1632 transcription
factors placing our gene list at the top (0.07%) of the transcription assessment list for
enrichment of MYBL1 binding. MYBL1 did not show evidence of direct binding to (the
promoter of) either UBXN8 or ADRM1, but there was enrichment of NPAS1 transcription
factor binding ADRM1. NPAS1 was not identified in our MYBL1 knockdown. Hundreds
of genes were identified as differentially expressed. It could very well be that MYBL1
regulates some gene on our list that directly (or even indirectly) regulates NPAS1. Or, it
could be ‘noise’, which is why all experiments must be validated using lots of different
datasets and experimental validation platforms.
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Table 1: shRNA MYBL1 Target Sequences
Supplied by Origene.com. Each was transduced into MYBL1 and assessed for
knockdown of MYBL1 transcript. LVA was most effective at decreasing
MYBL1 transcript.

Figure 8:

Analyses of LVA Sequence Ability to Knockdown Transcript and
Protein Levels
PCR and Western blot were used to compare MYBL1 levels in MDA
MB231 cells transduced with scramble compared to LVA particles
compared to untreated MDA MB231 cells.
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Table 2:

Transcription Factor Enrichment Analyses Using ChipX
ChipX program was used to interrogation our candidate genes for
transcription factor binding enrichment. Our gene list is enriched for several
genes, but also enrichment for binding

The research goal of our laboratory is to ultimately study genes that are key to the
pathogenesis of TNBC. At present, that gene is MYBL1, and toward that goal, we are
identifying and characterizing genes that associate with MYBL1 in TNBC cells. The
research described in this study totally revolves around analyses of MYBL1 and validating
UBXN8 and ADRM1 to determine if the genes might be in some way directly or indirectly
associated with MYBL1 in TNBC. The way to accomplish this is to compare the gene
expression levels of the two genes to MYBL1. These validations will determine whether
UBXN8 and ADRM1 are worth further studies. For UBXN8, currently, the answer is no.
Data presented in this section examined the gene expression patterns of UBXN8
and ADRM1 and compared those patterns to that observed in the knockdown study. For
example, data show that ADRM1 follows a pattern of expression concordant with
MYBL1; and UBXN8 follows a pattern of expression inverse to MYBL1. These data were
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generated using the DNA microarray, so their profiles were further examined and
experimentally examined using PCR and IHC protein analyses. In addition, the gene
expression levels were compared to patient sample datasets.
According to protocol, these types of analyses should be sufficient to draw
conclusions about the utility of our candidate genes. This study is separated into Aim 1
and Aim 2. Aim 1 involves experimental validation of the RNA and protein levels of our
candidate genes, using PCR and IHC. For Aim 2 we will compare our candidate genes
(MYBL1, MYBL2, ADRM1, and UBXN8) to archived breast cancer patient sample
profiles. The patient datasets contain transcript level data. These validations were used to
determine whether we would continue studies of UBXN8 and ADRM1 genes.
Choice of Cells Lines Used for the Comparative Analyses in the Current Study
There are at least 92 breast cancer and non-tumorigenic breast cell lines available
for studying different aspects of breast cancer (14). Many of these cell lines have been
thoroughly defined and characterized based on their origin, morphology, invasive
potential, and molecular signatures. Because of the incredible heterogeneity of the breast
cancer subtypes, choice of the cell lines to use for a particular study is important and can
be a daunting task. For this study, the MDA MB231 was chosen as the TNBC knockdown
because of its high levels of MYBL1 and it is well defined. The MCF7 luminal cell types
(i.e., MCF7) are used in comparative assays because even though the cell expresses
MYBL1 it is receptor positive and to a large degree, the cells express signatures that differ
from MDA MB231 and there is a tremendous amount of microarray data available to refer
to for validation of our experimental results.
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The MCF10A was used for many of the same reasons as the MCF7, except the
MCF10A cell line is a non-tumorigenic basal-like triple negative cell line and it serves as
a suitable non-tumor source. Search of PubMed, Gene Expression Omnibus, and a myriad
of other databases (and journals) you will find experimental comparisons using MCF7 and
MDA MB231. We use many of these resources as validation of our bioinformatic and
experimental results.
AIM 1 RESULTS SUMMARIZED: PCR AND IHC [EXPERIMENTAL
VALIDATION]
Question: Does ADRM1 follow a pattern of gene expression like that observed for
MYBL1; and does UBXN8 follow a pattern of gene expression inverse to that observed
for MYBL1? In aim 1, we compared the gene expression pattern of UBXN8 and ADRM1
to MYBL1 via PCR (for RNA comparison) and IHC (for protein level comparison). The
original microarray gene expression profiles extracted from the knockdown study are
presented in Figure 9. These results led to our interest in UBXN8 and ADRM1. Data
showed that when MYBL1 was knocked down, then UBXN8 was upregulated and
ADRM1 was downregulated along with MYBL2. The UBXN8 gene is a tumor suppressor
gene (Ts) (69) in several cancers, so we were interested to see the gene upregulated when
MYBL1 was knocked down. Did knockdown of MYB1 lead to a more ‘non-tumor’
genotype, activating the tumor suppressive function of UBXN8? We could speculate that
in TNBC, the pathogenesis of TNBC is driven by upregulation of MYBL1 and activation
of the Ts function of UBXN8 (i.e., downregulation).
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The choice to examine ADRM1 with UBXN8 together because both genes were
affected by MYBL1 knockdown, and both are functionally related to dysregulation in
protein-folding mechanisms. ADRM1 is currently being studied as a biomarker for
luminal breast cancers and although the gene is upregulated in TNBC, it is not being
considered for a role in TNBC (66). Nonetheless, it demonstrates a pattern consistent with
MYBL1 and that is criteria for studying the gene. Our TNBC cell line (MDA MB231) is
negative for c MYB, ESR1, PR and ERBB2 (i.e., Her2), and these genes were negative in
the scramble and LVA, so they were included in the figure as negative controls and
validation of our protocol.
PCR RNA Expression Analyses
The primer sequences and amplicon sizes for the genes examined in this study are
listed in Table 3 and the PCR gel is displayed in Figure 10. Densitometer analyses of the
PCR results are presented in Figure 11. If we first compare the PCR results to the
knockdown data, gene expression of MYBL1, ADRM1 and MYBL2 in MDA MB231 are
consistent with the knockdown results. Each of the genes show a similar direction of
expression as observed for MYBL1 in MDA MB231 (which was the cell line used for
knockdown). That is not the case for UBXN8; high levels of the gene are detected in
UBXN8 in MDA MB231 cells. One would expect low levels of UBXN8 in these
untreated TNBC, and higher levels in the MCF10A non-tumor triple negative cell line,
which we did not see. Because results of the UBXN8 gene are not consistent, it is not
considered a strong candidate for future consideration. ADRM1 and MYBL2 ‘follow’ a
similar pattern as MYBL1 (as observed for the knockdown).
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IHC Protein Expression Analyses
TNBC tissue array was used to examine MYBL1, ADRM1 and CD31 control
levels in invasive carcinoma patient samples. The tissues were a bit old (i.e., lacking
optimal protein expression) but some were suitable for analyses. ADRM1 and MYBL1
were detected in a few of the same samples, but there was one patient sample with high
ADRM1 and negative for MYBL1; this sample appeared well differentiated (Figure 12).
In another patient sample, ADRM1 and MYBL1 protein was detected, but ADRM1 protein
expression appeared to be expressed in different cells compared to MYBL1, not different
cell types (Figure 13). This sample appeared poorly differentiated. This doesn’t mean that
ADRM1 is not a good candidate, it’s just not the best candidate for being possibly
associated with MYBL1 in TNBC. Still, ADRM1 is worth studying further.
AIM 2 RESULTS SUMMARIZED: GEO PATIENT DATASET COMPARISONS
[BIOINFORMATIC ANALYSIS]
In aim 2, we compare our candidate genes MYBL1, MYBL2, ADRM1,
andUBXN8 against archived breast cancer patient sample profiles. In our laboratory, we
consider patient samples the ‘gold standard’; nothing is more important than the pattern
observed in real women. Our patient sample profiles are from GEO GDS2250,
GDS1329, and the MAIRE dataset. Patient samples used for my study include all
subtypes. None, however, contain TNBC sub-categories; these samples are difficult to
find. The patient samples include normal-like, luminal A/B, and basal-like and TNBC
patient profiles.
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Analyses of GDS2250
The transcript levels detected for GDS2250 are given in Table 5. A plot of these
data is in Figure 14. MYBL1, MYBL2, ADRM1, and UBXN8 transcript levels were
examined in archived datasets created from breast cancer patients and breast cancer cell
lines. The GEOGDS2250 dataset includes normal-like, luminal-like, and basal-like/
TNBC patient samples (Figure 14). We generated the mean for (a) normal samples and
(b) mean values for all cancers combined and presented the values as a ratio. Comparing
normal to all samples: MYBL1=253/7224; MYBL2=131/1685; ADRM1=5641/1307;
UBXN8=326/353. The normal breast patients demonstrate high levels of ADRM1 even
though the trend line shows upward projection. A few highly expressed normal samples
screw these results. The ADRM1 is being studied as a biomarker for luminal cancer, but
the authors conclude the gene shows little utility for TNBC. There was not total
concordance with MYBL1 because some cancers express ADRM1 and not MYBL1 and
vice versa, like the pattern observed in IHC.
Also see the RNA Seq data See Figure 5 (generated by ProteinAtlas.org).
Nonetheless, the normal values are quite high for this gene in these patient samples. The
MYBL1 and MYBL2 genes show a differential pattern of expression. First comparing the
patient data values with the knockdown- For example MYBL1, MYBL2 ADRM1 and
UBXN8 to levels in TNBC only. MYBL1, MYBL2 and ADRM1 levels were high in
TNBC, but the value of ADRM1 is negated based on its expression in normal samples.
For UBXN8, the gene expression levels were low in all the samples. If UBXN8 were a
Ts gene we would expect high levels in non-tumor, which we did not observe. So, the
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UBXN8 is not a good candidate to pursue, and the higher-than-expected values of
ADRM1 in normal make it a less than desirable gene candidate. But the gene is worth a
second look in other datasets. If UBXN8 functions as a tumor suppressor in TNBC one
would expect down-regulation in the cancers and up-regulation upon silencing of
MYBL1. This was not the case. UBXN8 will be excluded from further studies.
Analyses of Maire Dataset
For the MAIRE analyses only normal and TNBC were analyzed (Figure 15). The
data show that MYBL1, MYBL2 and ADRM1 show a similar pattern of expression like
that observed for the GDS2250 dataset. Also, high gene expression levels were observed
for ADRM1. There were some samples that express ADRM1 and not MYBL1, like the
IHC data; although because of the limited number of IHC data point, it would be difficult
to make this comparison.
Cluster Analyses of all Maire Datasets
Even with high levels of ADRM1 and UBXN8, there were differences between
the normal and tumor based on cluster analyses (Figure 16). These are likely driven by
MYBL1 and MYBL2 and higher values of ADRM1.
STRING Analyses of MYBL1, ADRM1, UBXN8 and MYBL2
The String analyses was performed to examine a possible relationship between
UBXN8 and ADRM1 because both genes have been showed to associated with protein
misfolding events. There are no published, theorized, or experimental data
demonstrating a relationship between these 2 genes (Figure 17).
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Table 3: List of Primer Sequences Utilized in the Study
GENE

LEFT PRIMER

RIGHT PRIMER

SIZE OF
MPLICON
(BP = BASE
PAIRS)

MYBL1

AAGTCTGGGCTTATTGGACATAA

TGCAAGTATGGCTGCTACATG

202BP

MYBL2

GAGGGGGTCTGTGAATCTGA

CCATCCTAAGCAGGGTCTGA

265BP

c-MYB

CTTGTTTGGGAGACTCTGCA

TGCAAACACAGGATCCATGC

227BP

ESR1

ACTTGTCCCATGAGCAGGTG

CAAAGCTGCGACAAAACCGA

272BP

ERBB4

ATGCCAATTGTGTGTGGTGT

TTCTTTCCCAAGAGCCAAAA

272BP

GAPDH

TCC CTG AGC TGA ACG GGA AG

GGAGGAGTGGGTGTCGCTGT

217BP

PGR

GTCAGTGGGCAGATGCTGTA

TGTGAGCTCGACACAACTCC

293BP

UBXN8

AGTCGCTGGAGGACATAGGA

AAAATGGCACAGTCCACAGA

266BP

ADRM1

CTGCTTCCCTACTTGCCATC

TCGTCCTTCTTGTCCTTCGT

272BP
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Figure 9:

Microarray Data of The Control (Scramble) Vs the Selected Sequence
LVA

Table 4: MICROARRAY shRNA knockdown RAW DATA
(Gene descriptions from genecard.org)

GENE AFFY PROBE ID FOLD CHANGE C/LVA GENE DESCRIPTION
MYBL1

213906_at

-4X

MYBL1 IS A PROTEIN CODING GENE THAT IS ASSOCIATED
WITH ADENOID CYSTIC CARINOMAS AND MITOTIC
PROPHASE.

MYBL2

201710_at

-6X

MYBL2 IS A TRANSCRIPTION FACTOR THAT IS INVOLVED
IN CELL SURVIVAL, PROLIFERATION, AND
DIFFERENTITAION.

ADRM1

201281_at

-5X

A DRM1 ENCODES A MEMBER OF THE ADHESION
REGULATING MOLECULE 1 PROTEIN FAMILY. THE
ENCODED PROTEIN IS A PART OF THE PROTEASOME
WHERE IS BEHAVES LIKE A UBIQUITIN
RECEPTOR ADRM1 IS ASSOCAIATED WITH
CARCINOGENESIS.

UBXN8

215983_s
_at

+4X

UBXN8 IS A PROTEIN IS LOCATED IN THE ENDOPLASMIC
RETICULUM (ER) MEMBRANE. ASSOCAITED
DEGRADATION OF MISFOLDED PROTEINS.
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Figure 10: PCR Visualized Using Densitometer for Numerical Values

Figure 11: Graph of the Visualized PCR Densitometer for MYBL1,
MYBL2, ADRM1, and UBXN8
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A. ADRM1

B. MYBL1

C. CD31 CONTROL

Figure 12: IHC Staining on the TMA for CD31 Blood Vessels as well as
Candidate Genes MYBL1 and ADRM1
These cells are poorly differentiated.
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A.) ADRM1

B.) MYBL1

C.) CD31
Figure 13: IHC Staining of the TMA ADRM1 and MYBL1 Protein were Detected
in Different Cells
These cells are well differentiated.
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Results from Aim 2:

Table 5:

GDS2250 Dataset of MYBL1. MYBL2, ADRM1, and UBXN8 Levels in
Patient Samples

GDS2250

BREAST CANCER TYPES

MYBL1

MYBL2

ADRM1

UBXN8

N1

162.6954

48.93241

6949.882

424.2785

N2

194.0993

142.2562

7492.367

245.4737

N3

52.32268

127.6319

4129.824

272.0865

N4

120.5229

143.4304

4614.921

333.983

N5

159.9514

87.58327

4167.16

269.1019

N6

70.33292

267.4814

6747.113

459.0596

N7

1017.384

103.5019

5390.535

262.1901

LUM1

1565.03

451.141

9286.899

1184.813

LUM2

754.7149

2019.388

16756.31

803.3496

LUM3

295.9558

772.8771

6811.789

1114.945

LUM4

15561.11

690.0955

10193.14

401.2923

LUM5

4121.984

918.8933

5938.608

616.3099

LUM6

25.84998

1215.803

10148.49

116.7389

LUM7

256.888

473.9112

7904.125

328.048

LUM8

4549.943

635.2191

15603.96

269.5058

LUM9

228.5626

228.4255

13785.88

22.89091

LUM10

2079.681

779.0226

10673.19

861.7024

LUM11

6670.766

1392.074

4812.827

235.7448

LUM12

22.70715

1485.208

12760.63

342.3111

LUM13

312.4736

2484.657

4185.536

324.3425
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LUM14

6741.246

800.791

31533.32

251.9524

LUM15

100.5666

171.3949

6463.072

280.2466

LUM16

218.4899

296.2489

7509.844

149.3227

LUM17

2126.494

702.1099

4113.996

295.6363

LUM18

4342.302

4547.214

11250.97

195.2186

LUM19

647.449

1132.293

23701.65

261.1565

LUM20

91.11204

1180.803

9646.689

166.017

TNBC1

4938.318

1991.195

12658.45

97.45395

TNBC2

3339.579

3660.006

21452.15

311.2044

TNBC3

25210.1

4334.407

22134.66

2062.244

TNBC4

12666.55

293.4127

12211.46

133.028

TNBC5

2517.748

916.0766

7718.613

295.9824

TNBC6

1193.124

2167.132

12478.22

85.60896

TNBC7

9037.971

1498.965

8123.448

179.3519

TNBC8

61.00464

974.9342

7741.185

41.29783

TNBC9

71118.3

3644.338

23077.19

106.2654

TNBC10

299.1874

556.9637

6927.609

56.83714

TNBC11

5122.152

925.2463

15215.65

116.1137

TNBC12

510.9696

3186.951

21940.73

200.415

TNBC13

58764.9

2988.33

13221.77

171.6693

TNBC14

108.136

1555.014

5955.855

20.71421

TNBC15

1889.429

2741.142

9101.277

78.77061

TNBC16

14284.78

2604.823

13750.77

80.79378

TNBC17

3494.97

4301.16

19125.54

206.5453

TNBC18

2043.501

1664.017

27769.68

843.8207
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Figure 14: GDS2250 Normal, Luminal, and Basal-TNBC Patients vs Candidate
Genes

Figure 15: Candidate Gene Expression in Normal vs TNBC in MAIRE
Patient Samples Bar Graph
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Figure 16: Candidate Gene Expression in Normal vs TNBC in MAIRE Patient
Samples
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Figure 17: String Analysis of Candidate Genes

CHAPTER 5
SUMMARY, CONCLUSIONS, AND RECOMMENDATIONS
The goal of this project was to compare the gene expression profiles of ADRM1
and UBXN8 genes to that observed for MYBL1. The focus of our laboratory is further
characterizing MYBL1 in TNBC and identify genes that might be either directly or
indirectly associating with the gene to affect the genotype of TNBC. Although we have
not demonstrated MYBL1’s effect on the cancer genotype we suspect MYBL1 does play
a role based on its function. Our next experiments will attempt to answer this question.
So, what about ADRM1 and UBXN8? ADRM1 is worth a second look, but
UBXN8 is not. The IHC results will be repeated using more suitable arrays and with more
patient samples. ADRM1 is proving to be a biomarker for luminal cancers, but we will
perform experiments to address the possibility that ADRM1 is indirectly affected by
MYBL1 in TNBC because defining genes affected by MYBL1 is one of our main goals.
ChipX suggests ADRM1 is directly regulated by NPAS1. The knockdown datasets will
be re-analyzed looking for a ‘link’ between the differentially expressed genes on the list
and NPAS1.
Two experimental procedures are critical to the success of the experiments
presented in this document. The success of the experiments outlined here depend on the
shRNA lentiviral MYBL1 knockdown procedure and the interpretation of the results
generated using the DNA microarray platform. We are in the process of repeating the
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shRNA lentiviral knockdowns and as we have repeatedly emphasized, even though the
microarray is an invaluable resource, the data generated from the platform must be
validated. This phase of the experiments will continue, MYBL1 and validation of its
expression and search for genes affected by its expression are key goals of our
laboratory.
The lab sees MYBL1 as a candidate gene for biomarker studies eventually
leading to possible targeted gene therapies for TNBC patients. This current study is one
of many to be conducted in our laboratory in relation to MYBL1 and its role in TNBC.
The laboratory is also looking into MYBL1’s role in tumor progression. This future
study will be done using a mice model. The mice model study will further validate
MYBL1’s position in tumor progression. If MYBL1 plays a part in the tumor
development, the knockdown of the gene will then halt the tumor from forming in the
mice model. Of the nineteen genes selected from the preliminary knockdown study,
TCF19 and KIF18B were the most promising candidates. Further analysis of the genes
is underway in our laboratory because they seem to be connected to key signaling
processes in TNBC. Studies will continue with these projects to achieve the overall goal
of characterizing MYBL1 in TNBC.
.
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